NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) was the recipient of a large growth in short interest in October. As of October 30th, there was short interest totaling 61 shares, a growth of 45.2% from the October 15th total of 42 shares. Based on an average daily volume of 803 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Investors Weigh In On NewAmsterdam Pharma
An institutional investor recently bought a new position in NewAmsterdam Pharma stock. RA Capital Management L.P. purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 333,333 shares of the company’s stock, valued at approximately $4,217,000.
NewAmsterdam Pharma Stock Down 2.0%
Shares of NAMSW stock traded down $0.19 during trading hours on Tuesday, reaching $9.30. The firm’s fifty day simple moving average is $10.83 and its two-hundred day simple moving average is $18.33. NewAmsterdam Pharma has a 12-month low of $7.31 and a 12-month high of $30.45.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing oral medicines for people with cardiovascular and metabolic diseases. Its research centers on treatments to lower LDL cholesterol and address cardiovascular risk, particularly for patients who need additional options alongside existing therapies. The company’s lead candidate, obicetrapib, is an investigational oral cholesterol-lowering medicine that inhibits CETP, a protein involved in lipid metabolism. NewAmsterdam has also studied obicetrapib in combination with ezetimibe.
See Also
- Five stocks we like better than NewAmsterdam Pharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
